This concept has been validated in phase II and phase III clinical trials, in which significant anti-melanoma effects were observed in hundreds of patients with local injections of T-VEC into the tumor compared to administration of GM-CSF only [51,52]. This evidence concerns the gene CSF2 and neoplasm.